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Outcome measures are recommended in the management of chronic inflammatory
demyelinating polyneuropathy (CIDP). Various scales have been proposed in recent years,
some now commonly utilised in daily clinical practice. The available evidence base relies
itself on randomised controlled trial data obtained over the past thirty years, with several
studies using different primary and secondary outcomes. We here review the different
outcome measures used in CIDP research in relation to those currently recommended for
clinical management. We consider the evidence base for CIDP treatment from the primary
and secondary outcomes used in these studies and attempt to assess how this may relate to
current clinical practice of routine evaluation of treatment effects and long-term monitoring.
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Introduction.
Accurate assessment of neurological function in patients with inflammatory neuropathies is
critical to track disease severity over time, to provide evidence of disease relapse, and to
detect clinical improvement following treatment with immunomodulatory agents [1].
In chronic inflammatory demyelinating polyneuropathy (CIDP), multiple clinical rating
scales have been proposed and used in research, some also applied in clinical practice.
Several randomised controlled trials (RCTs) have been conducted in CIDP over the past three
decades. The outcomes used as primary and secondary end-points in these trials have
however differed. These varying methodologies impact upon the clinical applicability of
findings and the relevance of currently recommended and utilised scales in day-to-day
practice. To what extent the previously conducted RCTs are helpful to inform clinicians in
their practice, is, as a result, uncertain.
The main goal of this article was to review the different scales used in CIDP research
constituting the existing evidence-base, in relation to those proposed for CIDP management




We considered the main published therapeutic RCTs performed to date, in CIDP between
1990 and 2019, in relation to the primary and secondary outcome measures utilised in these
studies. The potential implications for the current therapeutic evidence base for these
disorders were evaluated in relation to applicability in current clinical practice.
Outcome Measures for CIDP.
In the last fifty years, several outcome measures have been proposed for the different
inflammatory neuropathies. A classical outcome measure remains the medical research
council (MRC) scale for muscle power [2]. This scale, still widely used today, grades muscle
power on a scale of 0 to 5. However, in recent years, the validity of MRC grading using six
levels (0 to 5) has been challenged and a new grading with only 4 levels has been proposed
[3].
The Neuropathy Impairment Score consists of an assessment of motor strength, reflexes and
sensory function resulting in a total score from 0 (normal) to a maximum of 244 [4].
Other proposed scales have evaluated disability rather than muscle strength or clinical
examination findings. These include Rankin Disability Scale (RDS) [5], the Hughes
Disability Scale (HDS) [6], the Guy’s Neurological Disability Scale (GNDS) [7]. The latter,
used primarily in patients with multiple sclerosis, was adapted into the Inflammatory
Neuropathy Cause and Treatment scale (INCAT) scale, (Hughes 2001, [8] which also
consisted of a separate sensory component in the INCAT sensory scale [9]. The INCAT scale,
which also became known as the “Overall Disease Disability Scale” or “ODSS”,
subsequently led to development of the “Overall Neuropathy Limitation Scale”, or “ONLS”
[10]. The Rotterdam Handicap Scale (RHS) [8] was devised as a more extensive disability
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evaluation measure. More recently, the Rasch-Built Overall Disability Scale [11], based on
Rasch-transformation of functional measures, was derived by an international collaborative
group, offering a wider assessment of disability. Also recently, grip strength as measured by a
Martin Vigorimeter or a Jamar dynamometer has been found to correlate well with disability
and strength measures and has hence been proposed as a quick and reliable outcome measure
in inflammatory neuropathies [12,13]. Other scales used have been walking measures, such
as the timed 10-metre walk and the 6-minute walk test. Detailed myometry finally has been
used in evaluation of patients with various neuropathies including CIDP in clinical
observational studies as well as trials, requiring complex and widely unavailable equipment
[14].
Overview of Outcome Measures used in RCTs in CIDP.
Table 1. summarises the outcome measures used in CIDP research in the main RCTs
considered. Table 2. details the type of evaluation offered by each. Considering the main
immunoglobulin RCTs in CIDP, 2 used the NDS as primary outcome measure. Neither used
a clinical secondary outcome. The study by Dyck et al. [15] compared intravenous
immunoglobulins (IVIg) to plasma exchange (PLEX). The study by Hahn et al. [16]
compared IVIg to placebo. Another study [17] comparing IVIg versus placebo, used the HDS
as primary outcome measure and the Average Muscle Score (AMS), as secondary outcome.
A further study, also comparing IVIg to placebo, used the Rankin scale as primary and the
MRC sum score as secondary outcome measure [18]. Thompson et al. [19] in their study
comparing IVIg and placebo used the Hammersmith Motor Ability Scale (HMAS) as primary
outcome and several secondary outcomes, including timed 10-metre walk, MRC sum score,
myometry and 9-hole peg test. In a study comparing IVIg to prednisolone, Hughes et al. [20]
used as primary outcome the INCAT scale, with also multiple secondary clinical outcomes
including timed 10-metre walk, MRC sum score, grip strength, 9-hole peg test, modified
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Rankin scale (mRS) and RHS. The ICE Study [21] comparing IVIg to placebo in a response-
conditional cross-over design study over 24 weeks utilised the INCAT scale as primary
outcome and grip strength as secondary outcome. The Randomised Methotrexate CIDP
(RMC) Study evaluating the usefulness of methotrexate in reducing immunoglobulin or
steroid requirements, used the ONLS [22]. A RCT comparing 2 different IVIg products [23],
used the ODSS as primary outcome with MRC sum score and grip strength as secondary
clinical outcomes. The Italian study comparing IVIg to intravenous methylprednisolone (IMC
Trial), defined within the primary outcome, ineffectiveness, by deterioration of ONLS and
mRS scores [24]. A French RCT of IVIg versus oral prednisolone (Camdessanché et al., 2015)
used the INCAT scale as primary outcome [25]. Subcutaneous immunoglobulin was trialled
as first-line therapy versus IVIg in treatment-naïve CIDP [26], with change in isokinetic
dynamometry as primary outcome measure. Clinical secondary outcomes used were MRC
sum score, Jamar grip dynamometry, 9-hole peg test, 40 metre walk test and ODSS. An open-
label Japanese 52-week phase III trial for its part, used the adjusted INCAT scale [27]. The
most recent RCT of immunoglobulins in CIDP was the PATH study, which compared 2 SCIg
dosages versus placebo [28], using the adjusted form of the INCAT scale as primary outcome.
Clinical secondary outcomes were the grip strength, MRC sum score and I-RODS.
Steroids were compared to placebo in a trial published in 1982 [29] which used the NIS as
primary outcome. Comparison of daily versus monthly high-dose steroids was performed in
the PREDICT Trial [30] using as primary outcome the Rivermead Mobility Index (RMI) and
the INCAT disability scale. Both RCTs of PLEX versus sham PLEX [31,32] used the NIS as
primary outcome.
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Concept of Minimal clinically important difference (MCID).
In addition to statistical significance, the MCID is an important notion used to determine
whether a medical intervention improves outcomes, as perceived by patients themselves [33].
The MCID has been defined as the “smallest difference in score in the domain of interest
which patients perceive as beneficial and which would mandate, in the absence of
troublesome side effects and excessive cost, a change in the patient’s management” or, in
other words, the lowest threshold for change that is important to or valued by the treated
patient [34, 35]. The concept of MCID is crucial in understanding outcomes [35]. The
concept has been applied retrospectively to CIDP studies post-hoc, after derivation by
anchor-based and distribution methods. In the case of the INCAT scale, which uses integer
values, the MCID has been found of <1, and has, as a result, been rounded up to 1 [36, 37].
Similarly, the MCID for the MRC sum score has, post-hoc, previously been rounded up to 4
[37]. In addition, calculated MCIDs have been determined for grip strength [37], and applied
in retrospect [37].
MCIDs have not been studied, to our knowledge, in relation to other previously used scales,
particularly NIS/NDS, Rankin scale, HDS, although have been suggested recently for the 6-
minute walk distance test in CIDP [38]. For the I-RODS, MCIDs have been derived but so far,
not implemented in therapeutic trials. Application of the MCID concept may alter the
conclusions of CIDP research, in relation to genuine, patient-experienced and patient-relevant,
clinical effectiveness of intervention. This has been to date, to our knowledge, only applied
post-hoc to the ICE Study [37]. With regards to the INCAT disability scale, results were
identical with anchor-based and distribution-based methods which both yielded MCIDs <1,
whereas results for grip strength differed.
Application of research data to outcome measure use in daily practice.
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The initial therapeutic studies in CIDP, performed between 1994 and 2001 used primarily
motor scales with the NIS/NDS as well as HDS, and in one case the HMDS. The Rankin
scale was used in one. Many studies used the MRCSS as secondary outcome. These studies
provided the initial basis for subsequent research. They are not however directly applicable to
today’s practice, as treatment decisions with regards to the individual functional benefit
expected in such a heterogeneous disorder, is now widely accepted as necessarily requiring
consideration of specific disabilities that may be reversible. Accepting the results of these
initial studies as forming part of the evidence base requires the scales used as being
appropriate for CIDP. This has however been challenged and led to the development of new
scales.
Since 2001, the INCAT and ONLS have been used in multiple studies, as primary outcome.
Most of the more recent evidence-base for immunomodulatory therapies rely on these studies.
That significant comparative results were demonstrated post-hoc between treated and placebo
groups in the ICE Study, considering the MCID [37], is of practical clinical application, as
indicates importance of the results obtained in direct relevance to patient-perceived benefit,
albeit with the intrinsic limitations of the utilised scale.
Rasch-built scales have been advocated to overcome the limitations and the variable
importance of different items on traditional scales as well as differential weighing, making
their validity questionable. A Rasch-built linear weighted scale specifically for GBS and
CIDP was hence developed with transformation of raw scores to a centile metric, which was
tested for reliability and validated. This scale, the “I-RODS” has since been recommended for
use in research and is commonly used in clinical practice in many centres. Review of the
available, including recent evidence base for treatment of CIDP, does not however provide
the basis from research data, for straightforward clinical application. As such, despite
publication of the I-RODS in 2011, only the last RCT of SCIg [28], used the new scale and
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only as secondary outcome measure. The mean difference in centile score of the I-RODS
between high-dose SCIg and placebo groups was of 5, which in terms of raw score represents
variable changes from 0 (at the extremities of the scale) to a maximum of 4 raw points
(applicable between 47% and 43% exclusively, and lower at all other possible starting points).
Although significant, the mean difference in change of centile I-RODS scores between high
and low-dose SCIg groups was only of 2, corresponding to between 0 to 2 raw points. In
terms of clinical significance, and considering raw scores, these statistical differences of
mean are below previously published MCIDs for the scale.
Application of research into clinical practice ideally, first requires that meaningful clinically
relevant scales are used, and that significantly greater numbers of responders are shown to
attain MCID cut-offs in treated versus placebo groups. The former requirement has been
debated for the INCAT/ODSS/ONLS but these scales have remained in preference to all
others as primary outcome up till now. The latter requirement has been shown to be fulfilled
only, to date, post-hoc, for the ICE Study. However, and importantly, if the INCAT scale is
inadequate, the significance of reaching its MCID becomes highly uncertain. Similarly, it
may be argued that the application of the MCID concept is irrelevant for the MRC sum score,
in view of its poor reliability, as has been suggested [11].
In daily clinical practice, the MRCSS, as an exclusive motor evaluation, offers an easily
applicable tool, although its lack of functional relevance is a clear issue. The intrinsic
limitations of the MRC grading are also of obvious concern with regards to use for
therapeutic decisions REF Van Houtte no.3 et PAS 39!! [39]. The INCAT/ONLS scales offer
the significant advantage of rapid evaluation, although are limited by inadequacy for
assessment of proximal arm function-related and stamina-related tasks REF Breiner no.1 et
PAS 40!! [40]. Grip strength is a very attractive option for clinical practice, quick and easy to
implement and correlating well with general disability. However, complete confidence in the
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validity of this tool is necessarily dampened by the several probable existing covariates,
including depression [41]. The I-RODS presents the advantage of wide evaluation although
the lack of validation across different populations as well as the wide diversity of CIDP as a
clinical entity makes it of uncertain value for all patients.
Unfortunately, these many complexities are not considered in the advice and guidance
provided by existing guidelines and national bodies to clinicians, with regards to clinical
monitoring. Although the limitations of the available data and evidence restricts the detail and
accuracy of any possible formulated directives, it would be desirable that these are
themselves evidence-based. There appears to be a clear lack of evidence on the relevance
outcome measures in CIDP as used in research, thereby raising doubt on the methods
advocated and used in daily practice.
Conclusion.
Despite advances in the availability of newer disability outcome measures in recent years as
well as enhancement of knowledge about and awareness of the importance of actual clinical
relevance to affected patients, clinical practice in CIDP still relies heavily on the evidence
base from older studies. These used mainly motor scales, largely inadequate to establish the
true functional effectiveness of intervention. Data on comparative proportions of responders
actually attaining a minimum clinically-relevant level of amelioration on these scales is
lacking. Although helpful, meta-analyses focusing on the primary outcome measures, as used,
are therefore limited by these factors and when an attempt was made to convert these to a
single scale such as the mRS, the latter was itself limited by its lack of detail and its
inadequacy for measuring the small but clinically important changes that may occur in CIDP
[42].
11
More recent studies have essentially used scales initially derived nearly twenty years ago.
The INCAT, ODSS, ONLS have been widely criticised. Main reasons include failure to
correctly detect activity limitations due to proximal arm weakness or fatigue, substantial
individual item weighting and poor sensitivity for minor changes. The I-RODS was derived
and validated as a new clinically appropriate scale for CIDP research. However, of the six
studies we here considered conducted after the I-RODS was published in 2011, none utilised
it as primary outcome and only one included it as secondary outcome. Of the 6, five used the
INCAT/ODSS/ONLS, and one, isokinetic dynamometry. MRC sum scores were included as
secondary outcomes by all, and always in the original form, with the new MRC grading
system proposed [11], never in effect, implemented. There consequently appears to remain a
persistent gap between, on the one hand, research into outcome measures for CIDP and
research practice in CIDP RCTs, but also on the other, between the evidence base for
treatment of CIDP and monitoring methods in clinical practice, as illustrated by the common
implementation of the I-RODS but also the persistent reliance on MRC sum scores, by
clinicians.
In the U.K., previous guidelines by the Department of Health for use of IVIg for CIDP have
advised use of different outcome measures including MRC sum score, ONLS and even
INCAT Sensory Sum Score [43]. The issue of scale appropriateness was not considered, nor
that of clinically meaningful improvement, leaving to the discretion of clinicians to decide the
cut-offs to define response and precise timing as well as scale choice for such a response to
be deemed present.
Clinical management and monitoring of patients with CIDP remain a challenge, with many
uncertainties due to methods used as well as interpretation of findings. There are notable
discrepancies between how the treatments have been found effective in research studies and
how clinical care is monitored and difficulties are compounded by the lack of attention paid
12
to patient-perceived meaningfulness of detected change. Newer attempts at devising disease-
specific scales are being attempted, some such as the Rasch-informed CAPPRI (Chronic
Acquired Polyneuropathy Patient Reported Index) published and validated in different CIDP
populations METTRE REF Gwathmey et Bjelica ICI !. How useful such novel patient-
reported outcome measures may prove in evaluating change is unknown and therefore, so is
their usefulness in a research setting ENLEVER REF ICI ! [39,40]. Given the availability
issues as well as high cost of IVIg treatment of CIDP and the non-negligible side-effect risk,
the question of objective and relevant monitoring methods is paramount. The absence of
adequate biomarkers in CIDP and the undeniable placebo treatment effects and psychological
aspects of the disease, make it imperative that future research focuses on the pragmatic
aspects of clinical monitoring.
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Table 1. Summary of Outcome Measures used in principal RCTs considered in current
analysis
Author, year Intervention Scale
Dyck, 1994 [15] IVIg to PLEX Neuropathy disability score (NDS)
20
Hahn, 1996 [16] IVIg to placebo Neuropathy disability score (NDS)
Mendell, 2001 [17] IVIg to placebo Hughes Disability Scale (HDS) as primary outcome measure








IVIg to placebo Hammersmith Motor Ability Scale (HMAS) as primary
outcome and secondary outcomes including 10 metre
walking time, MRC sum score, myometry and 9-hole peg
test
Hughes, 2001 [20] IVIg to prednisolone INCAT scale as primary outcome and10 metre walking time,
MRC sum score, grip strength, 9-hole peg test, Rankin scale
and Rotterdam Handicap Scale as secondary outcomes
The ICE Study,
2008 [21]













ODSS as primary outcome with MRC sum score and grip










Isokinetic dynamometry as primary outcome measure and
MRC sum score, Jamar grip dynamometry, 9-hole peg test,




52-week phase III trial
prescribing IVIG
adjusted INCAT scale
van Schaik et al.,
2018 [28]
2 SCIg dosages versus
placebo
adjusted INCAT as primary outcome, and grip strength,
MRC sum score and I-RODS as secondary outcome
Dyck, 1982 [29] Steroids were compared
to placebo





Rivermead Mobility Index and the INCAT disability scale
Dyck, 1986 [31] PLEX versus sham
PLEX











Table 2. Outcome Measures used in CIDP research 1990-2019.
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Outcome Measure Type
MRC Sum Score Classical Motor Scale
Average Muscle Score (AMS) Classical Motor Scale
Grip Strength (Martin or Jamar) Quantitative Motor Scale
Myometry Quantitative Motor Scale
Ten metre timed walk Task-specific disability scale
Forty metre walk test Task-specific disability scale
Six-minute walk Task-specific disability scale
Rivermead Mobility Index (RMI) Task-specific disability scale
Nine-hole peg test Upper limb-specific disability scale
Hughes Disability Scale (HDS) Disability Scale
Neuropathy Impairment Scale (NIS);
Neuropathy Disability Scale (NDS)
Disability Scale
Hammersmith Motor Ability Scale (HMAS) Disability Scale
Modified Rankin scale (mRS) Disability Scale
Rotterdam Handicap Scale (RHS) Disability Scale
Inflammatory Neuropathy Cause and Treatment
(INCAT) Scale
Disability Scale
Overall Disease Disability Scale (ODSS) Disability Scale
Overall Neuropathy Limitation Score (ONLS) Disability Scale
Inflammatory Rash-built Overall Disability
Scale (I-RODS)
Patient Reported Outcome Measure
Chronic Acquired Polyneuropathy Patient
Reported Index (CAPPRI)
Patient Reported Outcome Measure
